In an adult with normal renal function whose primary complaint is insomnia, is gabapentin a better treatment option?

Gabapentin Should NOT Be Used for Primary Insomnia

Gabapentin is not recommended for the treatment of insomnia as the primary complaint. The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline explicitly recommends against using anticonvulsants, including tiagabine, for insomnia treatment 1. While gabapentin was not specifically evaluated in these guidelines, it falls within the anticonvulsant class that lacks sufficient evidence for insomnia treatment.

Evidence-Based First-Line Options

For an adult with normal renal function whose primary complaint is insomnia, the AASM guidelines provide clear recommendations for FDA-approved and evidence-supported medications 1:

For Sleep Onset Insomnia:

• Zaleplon 10 mg (WEAK recommendation)
• Ramelteon 8 mg (WEAK recommendation)
• Triazolam 0.25 mg (WEAK recommendation)

For Sleep Maintenance Insomnia:

• Suvorexant 10-20 mg (WEAK recommendation)
• Doxepin 3-6 mg (WEAK recommendation)

For Both Sleep Onset and Maintenance:

• Eszopiclone 2-3 mg (WEAK recommendation)
• Zolpidem 10 mg (WEAK recommendation)
• Temazepam 15 mg (WEAK recommendation)

Why Gabapentin Is Not Appropriate

The evidence base for gabapentin in primary insomnia is insufficient and contradicts guideline recommendations. While one small study (n=18) showed gabapentin increased slow-wave sleep in primary insomnia 2, and another phase-advance model study showed reduced wake after sleep onset 3, these do not constitute adequate evidence for routine clinical use.

Critical Limitations:

1. No guideline support: The AASM explicitly recommends against anticonvulsants for insomnia 1

2. Off-label use: Gabapentin is FDA-approved only for postherpetic neuralgia and epilepsy, not insomnia 4

3. Limited evidence quality: A 2014 meta-analysis found antiepileptics had lower efficacy than benzodiazepine receptor agonists and classical benzodiazepines for primary insomnia 5

4. Tolerability concerns: A systematic review found that at approximately 1,800 mg/day, gabapentin showed relatively high risk of treatment discontinuation or drug withdrawal 6

5. Renal considerations: Even with "normal" renal function, gabapentin clearance decreases with age (from ~225 mL/min in those <30 years to ~125 mL/min in those >70 years), requiring dose adjustments 4

When Gabapentin Might Be Considered

Gabapentin may improve sleep as a secondary benefit when treating comorbid conditions 7:

• Neuropathic pain (its FDA-approved indication)
• Alcohol use disorder with insomnia 8
• Restless legs syndrome
• Other pain syndromes

However, for primary insomnia without these comorbidities, gabapentin should not be used.

Common Pitfalls to Avoid

• Do not prescribe gabapentin simply because the patient requests a "non-addictive" sleep aid - the evidence-based options listed above have established efficacy and safety profiles for insomnia

• Do not assume gabapentin is safer than FDA-approved hypnotics - it has its own side effect profile including somnolence, dizziness, and potential for misuse

• Do not overlook cognitive behavioral therapy for insomnia (CBT-I) - this should be first-line treatment before any pharmacotherapy 9, 1

Recommended Approach

1. Start with CBT-I as first-line treatment (strong recommendation from American College of Physicians) 1

2. If pharmacotherapy is needed, use shared decision-making to select from the AASM-recommended agents based on:

   • Sleep onset vs. maintenance vs. both
   • Patient age and comorbidities
   • Side effect profile preferences
   • Cost and insurance coverage

3. Reserve gabapentin for patients with comorbid conditions where it has established efficacy (neuropathic pain, alcohol use disorder) and insomnia is a secondary complaint

The bottom line: For primary insomnia, choose from evidence-based, guideline-recommended hypnotics rather than gabapentin.